Vyleesi? Addyi? How women can get help for low sexual desire

Synopsis: The U.S. Food and Drug Administration just approved bremelanotide as a new pharmaceutical treatment for pre-menopausal women with low libido. Marketed under the brand name Vyleesi, the injectable medication is used to treat what has been known as hypoactive sexual desire disorder (HSDD). It’s the second libido-enhancing medication on the market for women. (The first, Addyi, was approved in 2015 and is a once-a-day pill designed to increase sexual desire.) Statistics vary, but more than a third of women report having low or limited libido and 10 percent have HSDD. Many — but, it’s important to note, not all — are looking for help to increase their sex drive. We spoke with Stacy Tessler Lindau, MD, a professor in the Department of Obstetrics and Gynecology and an expert in sexual function who runs the University of Chicago Medicine’s Program in Integrative Sexual Medicine and WomanLab.org, to learn more about what this latest pharmaceutical option means for women.

Click here to view the full story 

The Department of Obstetrics and Gynecology